CLINICAL_TRIALS trial_result · 2017-06-02

Clinical Trial Update: Effects of the V1a Agonist FE 202158 in Patients With Septic Shock [Phase 2]

Phase 2 clinical trial evaluating the V1a agonist FE 202158 in patients with septic shock has completed and results were posted in 2017.

Upgrade for the full analysis, importance score, and drug timeline.

Sponsor: Ferring Pharmaceuticals | Conditions: Septic Shock | Phase 2 | Status: COMPLETED | Results posted: 2017-06-02